BUSINESS TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy Tuesday, March 10, 2026 · janssen emea Advertisement Read Original Article → Related Dispatches [CA] · Jun 29 Little Movement Seen For Singapore Stock Market [US] · Jun 29 👔 Multiple Executive & Management Openings in Allen, TX [US] · Jun 29 Protect Yourself From the Energy Zappers